Who are the key players in North America Biomarkers Market industry?

The key players in the North America Biomarkers Market include Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche Ltd, and PerkinElmer Inc. These companies are industry leaders, investing significantly in diagnostic innovations and expanding their biomarker portfolios to address rising demand for precision medicine and improved healthcare outcomes.

What is the North America Biomarkers Market growth?

The North America Biomarkers Market is experiencing robust growth, driven by increasing adoption of biomarkers for early disease diagnosis and personalized medicine. For example, Thermo Fisher Scientific reported significant expansion in their biomarker services in 2023, supporting market acceleration across clinical research and pharmaceutical development segments.

Which segment accounted for the largest North America Biomarkers Market share?

The Diagnostics segment accounted for the largest share in the North America Biomarkers Market. With the rising prevalence of chronic diseases and cancer, biomarkers for early diagnosis and monitoring are in high demand, leading many healthcare companies to prioritize diagnostic applications and invest in advanced biomarker technologies.

What are the factors driving the North America Biomarkers Market?

Key drivers include increased investment in precision medicine and rising prevalence of chronic diseases. The launch of advanced biomarker-based diagnostic kits, such as those by Abbott Laboratories, are enhancing early detection capabilities and supporting the market’s growth, alongside favorable government funding for biomarker research.

Which type accounted for the largest North America Biomarkers Market share?

The Safety Biomarkers type accounted for the largest market share, widely used for monitoring drug safety and efficacy in clinical trials. Pharmaceutical companies increasingly leverage safety biomarkers to reduce development time and costs while ensuring patient safety, making them a crucial segment in the region’s biomarker market.

Home Healthcare

North America Biomarkers Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Biomarkers Market
Brand: Bussiness Insights

North America Biomarkers Market: by Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Diagnostic Biomarkers), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Other Applications), Distribution Channels (Direct Tender, Retail Sales, Online Sales, Distributors, Other Channels), Technology (Immunoassay, PCR, NGS, Mass Spectrometry, Chromatography, Other Technologies), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20260

North America Biomarkers Market Analysis 2025-2035

The North America Biomarkers Market is forecast to experience substantial growth from 2025 to 2035, driven by advances in medical diagnostics, rising prevalence of chronic diseases, and growing adoption of personalized medicine. Biomarkers play a critical role in disease detection, prognosis, and monitoring, fueling demand across healthcare, pharmaceutical, and research sectors. Innovation from leading firms and supportive regulatory environments further underpin expansion in this dynamic market.

Latest Market Dynamics

Key Drivers

Growing adoption of personalized medicine: Increasing demand for individualized treatment choices is driving the uptake of biomarkers, with Roche Diagnostics launching new companion diagnostic solutions in 2024.
Advancements in genomics and proteomics technologies: Investment in next-generation sequencing (NGS) and mass spectrometry by companies like Illumina Inc.

In 2025, diagnostic biomarkers dominate the North America biomarkers market, driven by heightened demand in disease screening and early detection. Predictive and prognostic biomarker segments follow, supported by expanding adoption in therapeutic monitoring and patient stratification. Efficacy and safety biomarkers, while critical in drug development phases, contribute modestly to the overall segment mix. The ongoing shift toward precision and personalized healthcare continues to reinforce the significance of type-based segmentation within the market.

Diagnostics remains the leading application for biomarkers in North America, holding a significant market share in 2025 due to urgent needs for early detection and disease management. Drug discovery and development rank second, as pharmaceutical R&D increasingly relies on biomarkers for efficacy and safety validation. Personalized medicine shows rapid growth, reflecting trends toward customized therapies and precision treatment protocols. Other applications, such as prognosis and risk assessment, support the expanding biomarker utility landscape.

The North America Biomarkers Market is witnessing robust revenue growth, forecasted to rise from 17,200 Million USD in 2020 to 49,800 Million USD by 2035. This expansion is attributed to increasing demand for advanced diagnostic solutions, the proliferation of chronic and infectious diseases, and strategic industry collaborations. Sustained investments in technology and innovation further reinforce market momentum, yielding a CAGR in the high single digits throughout the forecast period.

Year-over-year growth in the North America Biomarkers Market is projected to trend between 6.3% and 7.2% from 2020 to 2035. Peaks are expected during 2025-2028 as technological breakthroughs and regulatory incentives stimulate adoption, particularly in diagnostics and personalized medicine. Subsequent years see moderate stabilization, reflecting market maturity and ongoing integration of biomarker-driven healthcare advancements.

The United States commands the largest share of the North America Biomarkers Market in 2025, driven by advanced healthcare infrastructure and high R&D investment. Canada follows, benefiting from strong government initiatives and expanding biotech activities. Mexico, while smaller in market contribution, is witnessing rapid growth due to improving medical diagnostics and healthcare access.

Market share among key players in the North America Biomarkers Market is relatively consolidated, with Thermo Fisher Scientific leading in 2025 owing to broad product offerings and technological leadership. Roche Diagnostics and Abbott Laboratories remain prominent through innovation and strategic collaborations. Other major firms, including Bio-Rad Laboratories, Agilent Technologies, and QIAGEN, hold notable shares, reflecting a competitive and innovation-centric landscape.

Pharmaceutical companies represent the leading buyers of biomarkers in North America, leveraging biomarkers for targeted drug development and regulatory approvals. Research institutions hold a significant portion due to ongoing biomarker discovery initiatives. Hospitals and diagnostic centers also account for substantial market share, especially as clinical adoption accelerates.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	24600
Regions	United States, Canada, Mexico
Segments	Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Diagnostic Biomarkers, Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Other Applications
Players	Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Agilent Technologies, Siemens Healthineers, QIAGEN, PerkinElmer, Enzo Biochem, Waters Corporation, Becton Dickinson (BD), BioMérieux, Meso Scale Diagnostics, Quanterix Corporation, Illumina Inc.

June 2024: Thermo Fisher Scientific launches AI-enhanced biomarker discovery platform for oncology diagnostics.
July 2024: Abbott Laboratories announces partnership with leading cancer centers for advanced biomarker assay development.
August 2024: Roche Diagnostics secures FDA approval for a new Alzheimer's disease biomarker test.
August 2024: QIAGEN expands its North American facility for high-throughput genomic biomarker testing.
September 2024: Bio-Rad Laboratories introduces next-generation liquid biopsy solutions for early cancer detection.

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

North America Biomarkers Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Biomarkers Market Analysis 2025-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

North America Biomarkers Market Share (%) by Type, 2025

North America Biomarkers Market Share (%) by Application, 2025

North America Biomarkers Market Revenue (USD Million), 2020-2035

North America Biomarkers Market Year-Over-Year (YOY %) Growth, 2020-2035

North America Biomarkers Market Share (%) by Region, 2025

North America Biomarkers Market Players Share (%), 2025

North America Biomarkers Market Buyers Share (%), 2025

Study Coverage

Key Recent Developments

Frequently asked questions